期刊文献+

老年肾癌的诊疗分析 被引量:1

下载PDF
导出
摘要 随着人口逐渐老龄化,老年人的健康问题越来越受到重视,而恶性肿瘤对老年人的健康和生命构成了极大的威胁。肾细胞癌约占所有成人恶性肿瘤的3%,是泌尿系统最常见的恶性肿瘤之一,其发病率在我国仅次于膀胱癌居第二位,约有20%~30%的患者临床发现时已有远处转移,且其治疗效果和预后均不甚理想。同时,与其他年龄段肾癌患者相比,老年肾癌患者常伴有较严重的心肺等重要脏器的功能障碍,其治疗效果及预后均较差。
出处 《现代泌尿生殖肿瘤杂志》 2012年第3期174-175,共2页 Journal of Contemporary Urologic and Reproductive Oncology
  • 相关文献

参考文献15

  • 1Hollenbeak CS, Nikkel LE, Schaefer EW, et al. Determinants of medicare all-cause costs among elderly patients with renal cell car cinoma[J]. J Manag Care Pharm, 2011,17(8) : 610-620.
  • 2Suen KC, Lau LL, Yermakov V. Cancer and old age. An au- topsy study of 3,535 patients over 65 years old[J]. Cancer, 1974,33(4):1164-1168.
  • 3Torpy JM, Lynm C, Golub RM. JAMA patient page. Kid- neycancer[J]. JAMA,2011,306(2):226.
  • 4Deveson Kell S. Renal cell carcinoma, treatment options[J]. Br J Nuts,2011,20(9) :536-539.
  • 5Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma[J]. World J Urol,2010,28(3) :319-327.
  • 6Sacco E, Pinto F, Totaro A, et al. Imaging of renal cell car- cinoma: state of the art and recent advances[J]. Urol Int, 2011,86 (2) : 125-139.
  • 7Winter H, Meimarakis G, Angele MK, et al. Tumor infihra ted hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary me- tastasectomy in patients with renal cell carcinoma[J]. J Urol, 2010,184(5) : 1888-1894.
  • 8Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcino- ma and management of recurrent disease[J]. Urol Clin North Am,2003,30(4) :843-852.
  • 9Russo P, Synder M, Vickers A, et al. Cytoreductive nephrecto- my and nephrectomy/eomplete metastasectomy for metastatic re- nal cancer[J]. ScientificWorldJournal, 2007,7 : 768-778.
  • 10Russo P. Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy[J]. Nat Clin Pract Urol, 2004,1 (1) :26-30.

二级参考文献10

  • 1Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.
  • 2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134.
  • 3Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
  • 4Awada A, Hendlisz A, Git T, et al. Safety and pharmacokinetics of BAY 43 9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92: 1855-1861.
  • 5Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24; 2505-2512.
  • 6Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oneol, 2002, 20, 289-296.
  • 7Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oneol, 2007, 25(Suppl) : 241.
  • 8Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. JpnJ Clin Oncol, 2007, 37: 755-762.
  • 9Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596.
  • 10Shmidinger M, Vogl UM, Schukro C, et al. Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. J Clin Oncol, 2007, 25(Suppl) 293.

共引文献55

同被引文献9

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部